


**Product Name** : RP-1664  
**Cat. No.** : PC-24639  
**CAS No.** : 2980682-00-4  
**Molecular Formula** : C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>S  
**Molecular Weight** : 514.56  
**Target** : Polo-like Kinase (PLK)  
**Solubility** : 10 mM in DMSO



CAS: 2980682-00-4

### Biological Activity

RP-1664 (RP1664) is potent, selective and orally available inhibitor of **PLK4** with IC<sub>50</sub> of 3 nM, >1900-fold selective over Aurora A/B.

RP-1664 has EC<sub>50</sub> of 0.13 uM in PLK4 centriole depletion assay definition (CDA), and EC<sub>50</sub> of 0.051 uM for viability assay in MCF7 cells

RP-1664 binds PLK4 with 59-fold selectivity over FAK and 3-fold selectivity over TNK1 in NanoBRET assays.

RP-1664 potently inhibits TRIM37-high cell lines with IC<sub>50</sub> of 80 and 26 nM in cell growth assays, respectively, for CAL-148 and TRIM37 gain-carrying neuroblastoma CHP-134 cells.

RP-1664 (6, 11, and 21 mg/kg PO BID) demonstrates responsive tumor growth inhibition, stasis and regressions in CAL-148 breast and CHP-134 neuroblastoma model.

### References

Vallée F, et al. *J Med Chem*. 2025 May 16. doi: 10.1021/acs.jmedchem.5c00529.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com